| Therapy | Outpatient management | Inpatient management | Benefits | Disadvantages/common adverse effects | Typical dosage |
|---|---|---|---|---|---|
| Antibiotic, broad spectrum (e.g., amoxicillin/clavulanate [Augmentin], macrolides, second- or third-generation cephalosporins, quinolones) | Consider if sputum is purulent or after treatment failure | Use if local microbial patterns show resistance to narrow-spectrum agents | Decreases risk of treatment failure and mortality compared with narrow-spectrum agents | Antibiotic resistance, diarrhea, yeast vaginitis; side effects specific to the antibiotic prescribed | Amoxicillin/clavulanate: 875 mg orally twice daily or 500 mg orally three times daily for 5 days |
| Use if local microbial patterns show resistance to narrow-spectrum agents | |||||
| Levofloxacin (Levaquin): 500 mg daily for 5 days | |||||
| Antibiotic, narrow spectrum (e.g., amoxicillin, ampicillin, trimethoprim/sulfamethoxazole [Bactrim, Septra], doxycycline, tetracycline) | Consider if sputum is purulent or after treatment failure | Use if local microbial patterns show minimal resistance to these agents and if patient has not taken antibiotics recently | Believed to decrease mortality risk, but has not been tested in placebo-controlled trials | Antibiotic resistance, diarrhea, yeast vaginitis; side effects specific to the antibiotic prescribed | Amoxicillin: 500 mg orally three times daily for 3 to 14 days Doxycycline: 100 mg orally twice daily for 3 to 14 days |
| Use if local microbial patterns show minimal resistance to these agents and if patient has not taken antibiotics recently | |||||
| Anticholinergic, short acting (e.g., ipratropium [Atrovent]) | May add to beta agonist; if patient is already taking an anticholinergic, increase dosage | May add to beta agonist; if patient is already taking an anticholinergic, increase dosage | Improves dyspnea and exercise tolerance | Dry mouth, tremor, urinary retention | Ipratropium: 500 mcg by nebulizer every 4 hours as needed; alternatively, 2 puffs (18 mcg per puff) by MDI every 4 hours as needed* |
| Beta agonist, short acting (e.g., albuterol, levalbuterol [Xopenex]) | Increase dosage | Increase dosage | Improves dyspnea and exercise tolerance | Headache, nausea, palpitations, tremor, vomiting | Albuterol: 2.5 mg by nebulizer every 1 to 4 hours as needed, or 4 to 8 puffs (90 mcg per puff) by MDI every 1 to 4 hours as needed* |
| Corticosteroid | Consider using oral corticosteroids in moderately ill patients, especially those with purulent sputum | Use oral corticosteroids if patient can tolerate; if not suitable for oral therapy, administer intravenously | Decreases risk of subsequent exacerbation, rate of treatment failures, and length of hospital stay Improves FEV1 and hypoxemia | Gastrointestinal bleeding, heartburn, hyperglycemia, infection, psychomotor disturbance, steroid myopathy | Oral prednisone: 30 to 60 mg once daily Intravenous methylprednisolone (Solu-Medrol): 60 to 125 mg 2 to 4 times daily |
| Mechanical ventilation | NA | Use if patient cannot tolerate NIPPV; has worsening hypoxemia, acidosis, confusion, or hypercapnia despite NIPPV; or has comorbid conditions such as myocardial infarction or sepsis | Decreases short-term mortality risk in severely ill patients | Aspiration, cardiovascular complications, need for sedation, pneumonia | Titrate to correct hypercarbia and hypoxemia |
| NIPPV | NA | Use in patients with worsening respiratory acidosis and hypoxemia when oxygenation via high-flow mask is inadequate | Improves respiratory acidosis and decreases respiratory rate, breathlessness, need for intubation, mortality, and length of hospital stay | Expensive, poorly tolerated by some patients | Titrate to correct hypercarbia and hypoxemia |
| Oxygen supplementation | NA | Use in patients with hypoxemia (PaO2 less than 60 mm Hg) | Decreases mortality risk | Hypercarbia | Titrate to PaO2 > 60 mm Hg or oxygen saturation ≥ 90 percent |